Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis
Authors
Keywords
-
Journal
Expert Review of Vaccines
Volume -, Issue -, Pages 1-18
Publisher
Informa UK Limited
Online
2022-07-07
DOI
10.1080/14760584.2022.2098719
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials
- (2022) Julia W. Haas et al. JAMA Network Open
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
- (2021) Raches Ella et al. LANCET INFECTIOUS DISEASES
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
- (2021) Peter Richmond et al. LANCET
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2021) Zhiwei Wu et al. LANCET INFECTIOUS DISEASES
- A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
- (2021) Laurence Chu et al. VACCINE
- An interactive website tracking COVID-19 vaccine development
- (2021) Madhumita Shrotri et al. Lancet Global Health
- Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
- (2021) Shilong Yang et al. LANCET INFECTIOUS DISEASES
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Vivek Shinde et al. NEW ENGLAND JOURNAL OF MEDICINE
- The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: A phase I randomized, double-blinded, controlled trial
- (2021) Jing Pu et al. VACCINE
- Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial
- (2021) Ya-Jun Shu et al. CHINESE MEDICAL JOURNAL
- Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults
- (2021) Nawal Al Kaabi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and effectiveness of SARS‐CoV‐2 vaccines: A systematic review and meta‐analysis
- (2021) Yunzhi Ling et al. JOURNAL OF MEDICAL VIROLOGY
- Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
- (2021) Mine Durusu Tanriover et al. LANCET
- Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
- (2021) ShengLi Xia et al. LANCET INFECTIOUS DISEASES
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
- (2021) Bihua Han et al. LANCET INFECTIOUS DISEASES
- Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
- (2021) Kashif Ali et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
- (2021) Robert W. Frenck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
- (2021) Paul T. Heath et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
- (2021) Hana M. El Sahly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
- (2021) Stephen J. Thomas et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18–59 Years: An Interim Analysis in Indonesia
- (2021) Eddy Fadlyana et al. VACCINE
- Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
- (2021) Musha Chen et al. Infectious Diseases of Poverty
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
- (2021) Shabir A Madhi et al. Lancet HIV
- Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial
- (2021) Michiko Asano et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
- (2021) Scott A Halperin et al. LANCET
- Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
- (2021) Raches Ella et al. LANCET
- Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
- (2021) Ann R. Falsey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
- (2021) Lisa M. Dunkle et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults
- (2021) Miwa Haranaka et al. Nature Communications
- Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial
- (2021) Neil Formica et al. PLOS MEDICINE
- Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
- (2021) Szu-Min Hsieh et al. Lancet Respiratory Medicine
- The Impact of Age Difference on the Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
- (2021) Jiting Wang et al. Frontiers in Immunology
- Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
- (2021) Peter G Kremsner et al. LANCET INFECTIOUS DISEASES
- Software tools to support title and abstract screening for systematic reviews in healthcare: an evaluation
- (2020) Hannah Harrison et al. BMC Medical Research Methodology
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Feng-Cai Zhu et al. LANCET
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search